Xiaohui Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaohui Tang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Katherine A. Hutcheson
University of Texas MD Anderson Cancer Center
2 shared publications - Sheila N. Buoy
Section of Speech Pathology & Audiology, Department of Head and Neck Surgery, University of Texas, MD Anderson Cancer Center, Houston, USA
2 shared publications - Barbara Ebersole
Department of Otolaryngology-Head & Neck Surgery, Temple University School of Medicine, Philadelphia, Pennsylvania; Department of Speech Pathology, Fox Chase Cancer Center, Temple Head and Neck Institute, Temple University Health System, Philadelphia, Pennsylvania
1 shared publication - Brinda Rao Korivi
Abdominal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Cameron Macdonald
Qualitative Health Research Center, Madison, US
1 shared publication - Carla L. Warneke
Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication
Latest Publications
- 29 March 2025
- Published by Springer Nature in Dysphagia
- Vol. 40 (5) , 1240-1249
Fluoroscopy Time of Radiologist-Monitored Modified Barium Swallow Exams in Oncology: A 3-year Single Institution Retrospective Study
Fluoroscopy time is an important metric for radiation safety, but how it is related to dysphagia severity as graded by Dynamic Grade of Swallowing Toxicity (DIGEST) criteria and other factors in oncology practice is undocumented. We evaluated the fluoroscopy time for the bolus protocol used at the originating institution of the DIGEST method and assessed the relationship between fluoroscopy time and DIGEST grade, exam indication, and additional parameters. Eleven trials, including specified VARIBAR® barium volumes, were included in the standard bolus protocol. Electronic health record (EHR) 2018–2021 databases were sampled in a retrospective STARI-guided DIGEST implementation evaluation for clinically reported DIGEST grades in the EHR and matched to fluoroscopy time. The study sample included 4,162 modified barium swallow (MBS) examinations. Using generalized linear modeling, we tested log-transformed fluoroscopy time associations with Tukey’s adjustment for multiple pairwise comparisons. MBS duration ranged from 0.16 to 11.80 min (Median 2.21, IQR 1.98). Fluoroscopy time was associated with exam indication, cancer diagnosis, setting, and DIGEST grade. Fluoroscopy times increased as the DIGEST severity grade worsened (R2 = 0.45, p < .0001). MBS indication was also associated with fluoroscopy time (R2 = 0.12, p < .0001), with the shortest times for baseline exams and the longest for excluding leaks (Median1.6 vs. 3.5 min). Median fluoroscopy time was shorter among endocrine and metastatic cancer patients and longer among head and neck cancer patients (2 vs. 3 min, R2 = 0.02, p < .0001). Inpatient examinations were longer than outpatient (Median 3.1 vs. 2.2 min, R2 = 0.02, p < .0001). The bolus protocol was clinically acceptable within ALARA standards. Clinicians should be mindful of increased fluoroscopy time and optimize exams as clinically indicated in patients with severe dysphagia, leak exclusion, and inpatient studies.
- 29 March 2025
- Published by Springer Nature in Dysphagia
- Vol. 40 (5) , 1240-1249
Fluoroscopy Time of Radiologist-Monitored Modified Barium Swallow Exams in Oncology: A 3-year Single Institution Retrospective Study
Fluoroscopy time is an important metric for radiation safety, but how it is related to dysphagia severity as graded by Dynamic Grade of Swallowing Toxicity (DIGEST) criteria and other factors in oncology practice is undocumented. We evaluated the fluoroscopy time for the bolus protocol used at the originating institution of the DIGEST method and assessed the relationship between fluoroscopy time and DIGEST grade, exam indication, and additional parameters. Eleven trials, including specified VARIBAR® barium volumes, were included in the standard bolus protocol. Electronic health record (EHR) 2018–2021 databases were sampled in a retrospective STARI-guided DIGEST implementation evaluation for clinically reported DIGEST grades in the EHR and matched to fluoroscopy time. The study sample included 4,162 modified barium swallow (MBS) examinations. Using generalized linear modeling, we tested log-transformed fluoroscopy time associations with Tukey’s adjustment for multiple pairwise comparisons. MBS duration ranged from 0.16 to 11.80 min (Median 2.21, IQR 1.98). Fluoroscopy time was associated with exam indication, cancer diagnosis, setting, and DIGEST grade. Fluoroscopy times increased as the DIGEST severity grade worsened (R2 = 0.45, p < .0001). MBS indication was also associated with fluoroscopy time (R2 = 0.12, p < .0001), with the shortest times for baseline exams and the longest for excluding leaks (Median1.6 vs. 3.5 min). Median fluoroscopy time was shorter among endocrine and metastatic cancer patients and longer among head and neck cancer patients (2 vs. 3 min, R2 = 0.02, p < .0001). Inpatient examinations were longer than outpatient (Median 3.1 vs. 2.2 min, R2 = 0.02, p < .0001). The bolus protocol was clinically acceptable within ALARA standards. Clinicians should be mindful of increased fluoroscopy time and optimize exams as clinically indicated in patients with severe dysphagia, leak exclusion, and inpatient studies.
- 27 June 2024
- Published by Springer Nature in Dysphagia
- Vol. 40 (1) , 220-230
Clinical Implementation of DIGEST as an Evidence-Based Practice Tool for Videofluoroscopy in Oncology: A Six-Year Single Institution Implementation Evaluation
Clinical implementation of evidence-based practice (EBP) tools is a healthcare priority. The Dynamic Grade of Swallowing Toxicity (DIGEST) is an EBP tool developed in 2016 for videofluoroscopy in head and neck (H&N) oncology with clinical implementation as a goal. We sought to examine: (1) feasibility of clinical implementation of DIGEST in a national comprehensive cancer center, and (2) fidelity of DIGEST adoption in real-world practice. A retrospective implementation evaluation was conducted in accordance with the STARI framework. Electronic health record (EHR) databases were queried for all consecutive modified barium swallow (MBS) studies conducted at MD Anderson Cancer Center from 2016 to 2021. Implementation outcomes included: feasibility as measured by DIGEST reporting in EHR (as a marker of clinical use) and fidelity as measured by accuracy of DIGEST reporting relative to the decision-tree logic (penetration-aspiration scale [PAS], residue, and Safety [S] and Efficiency [E] grades). Contextual factors examined included year, setting, cancer type, MBS indication, and provider. 13,055 MBS were conducted by 29 providers in 7,842 unique patients across the lifespan in diverse oncology populations (69% M; age 1–96 years; 58% H&N cancer; 10% inpatient, 90% outpatient). DIGEST was reported in 12,137/13,088 exams over the 6-year implementation period representing 93% (95% CI: 93–94%) adoption in all exams and 99% (95% CI: 98–99%) of exams excluding the total laryngectomy population (n = 730). DIGEST reporting varied modestly by year, cancer type, and setting/provider (> 91% in all subgroups, p < 0.001). Accuracy of DIGEST reporting was high for overall DIGEST (incorrect SE profile 1.6%, 200/12,137), DIGEST-safety (incorrect PAS 0.4% 51/12,137) and DIGEST-efficiency (incorrect residue 1.2%, 148/12,137). Clinical implementation of DIGEST was feasible with high fidelity in a busy oncology practice across a large number of providers. Adoption of the tool across the lifespan in diverse cancer diagnoses may motivate validation beyond H&N oncology.
- 27 June 2024
- Published by Springer Nature in Dysphagia
- Vol. 40 (1) , 220-230
Clinical Implementation of DIGEST as an Evidence-Based Practice Tool for Videofluoroscopy in Oncology: A Six-Year Single Institution Implementation Evaluation
Clinical implementation of evidence-based practice (EBP) tools is a healthcare priority. The Dynamic Grade of Swallowing Toxicity (DIGEST) is an EBP tool developed in 2016 for videofluoroscopy in head and neck (H&N) oncology with clinical implementation as a goal. We sought to examine: (1) feasibility of clinical implementation of DIGEST in a national comprehensive cancer center, and (2) fidelity of DIGEST adoption in real-world practice. A retrospective implementation evaluation was conducted in accordance with the STARI framework. Electronic health record (EHR) databases were queried for all consecutive modified barium swallow (MBS) studies conducted at MD Anderson Cancer Center from 2016 to 2021. Implementation outcomes included: feasibility as measured by DIGEST reporting in EHR (as a marker of clinical use) and fidelity as measured by accuracy of DIGEST reporting relative to the decision-tree logic (penetration-aspiration scale [PAS], residue, and Safety [S] and Efficiency [E] grades). Contextual factors examined included year, setting, cancer type, MBS indication, and provider. 13,055 MBS were conducted by 29 providers in 7,842 unique patients across the lifespan in diverse oncology populations (69% M; age 1–96 years; 58% H&N cancer; 10% inpatient, 90% outpatient). DIGEST was reported in 12,137/13,088 exams over the 6-year implementation period representing 93% (95% CI: 93–94%) adoption in all exams and 99% (95% CI: 98–99%) of exams excluding the total laryngectomy population (n = 730). DIGEST reporting varied modestly by year, cancer type, and setting/provider (> 91% in all subgroups, p < 0.001). Accuracy of DIGEST reporting was high for overall DIGEST (incorrect SE profile 1.6%, 200/12,137), DIGEST-safety (incorrect PAS 0.4% 51/12,137) and DIGEST-efficiency (incorrect residue 1.2%, 148/12,137). Clinical implementation of DIGEST was feasible with high fidelity in a busy oncology practice across a large number of providers. Adoption of the tool across the lifespan in diverse cancer diagnoses may motivate validation beyond H&N oncology.